Abstract
Immunisation has proved to be a generally safe and effective means of disease control, particularly where environmental approaches are impractical. Recent developments in vaccine production, aimed at selecting or synthesising in pure form the antigens needed to evoke a protective response, give hope of more effective and less toxic vaccines in future. Adequate trials of improved vaccines may, however, be difficult to carry out under modern conditions. Policies for the use of vaccines are sometimes controversial, particularly when there is concern about reactions, as with pertussis vaccine. Acceptance rates for measles and rubella vaccines in the UK have hitherto been disappointingly low and need to be increased if the aims of elimination of measles and congenital rubella are to be achieved. Cost-benefit analyses generally support the use of immunisation in disease control.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fine P. E., Clarkson J. A. Measles in England and Wales--III: Assessing published predictions of the impact of vaccination on incidence. Int J Epidemiol. 1983 Sep;12(3):332–339. doi: 10.1093/ije/12.3.332. [DOI] [PubMed] [Google Scholar]
- Fine P. E., Clarkson J. A. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet. 1982 Mar 20;1(8273):666–669. doi: 10.1016/s0140-6736(82)92214-0. [DOI] [PubMed] [Google Scholar]
- Hinman A. R., Bart K. J., Orenstein W. A., Preblud S. R. Rational strategy for rubella vaccination. Lancet. 1983 Jan 1;1(8314-5):39–40. doi: 10.1016/s0140-6736(83)91572-6. [DOI] [PubMed] [Google Scholar]
- Hinman A. R., Brandling-Bennet A. D., Bernier R. H., Kirby C. D., Eddins D. L. Current features of measles in the United States: feasibility of measles elimination. Epidemiol Rev. 1980;2:153–170. doi: 10.1093/oxfordjournals.epirev.a036220. [DOI] [PubMed] [Google Scholar]
- Hopkins D. R., Hinman A. R., Koplan J. P., Lane J. M. The case for global measles eradication. Lancet. 1982 Jun 19;1(8286):1396–1398. doi: 10.1016/s0140-6736(82)92510-7. [DOI] [PubMed] [Google Scholar]
- Koplan J. P., Schoenbaum S. C., Weinstein M. C., Fraser D. W. Pertussis vaccine--an analysis of benefits, risks and costs. N Engl J Med. 1979 Oct 25;301(17):906–911. doi: 10.1056/NEJM197910253011703. [DOI] [PubMed] [Google Scholar]
- Miller D. L., Alderslade R., Ross E. M. Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol Rev. 1982;4:1–24. doi: 10.1093/oxfordjournals.epirev.a036242. [DOI] [PubMed] [Google Scholar]
- Miller D. L., Ross E. M., Alderslade R., Bellman M. H., Rawson N. S. Pertussis immunisation and serious acute neurological illness in children. Br Med J (Clin Res Ed) 1981 May 16;282(6276):1595–1599. doi: 10.1136/bmj.282.6276.1595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Preblud S. R., Serdula M. K., Frank J. A., Jr, Brandling-Bennett A. D., Hinman A. R. Rubella vaccination in the United States: a ten-year review. Epidemiol Rev. 1980;2:171–194. doi: 10.1093/oxfordjournals.epirev.a036221. [DOI] [PubMed] [Google Scholar]
- Salk D., Salk J. Vaccinology of poliomyelitis. Vaccine. 1984 Mar;2(1):59–74. doi: 10.1016/s0264-410x(98)90035-4. [DOI] [PubMed] [Google Scholar]
- Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 1984 Jan 21;1(8369):122–126. doi: 10.1016/s0140-6736(84)90061-8. [DOI] [PubMed] [Google Scholar]
- Witte J. J., Axnick N. W. The benefits from 10 years of measles immunization in the United States. Public Health Rep. 1975 May-Jun;90(3):205–207. [PMC free article] [PubMed] [Google Scholar]